Generics - Zydus Cadila, Oncology

Filter

Current filters:

Zydus CadilaOncology

Popular Filters

1 to 25 of 2611 results

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

Depomed settlements with two Gralise ANDA filers

15-04-2014

US specialty drugmaker Depomed has entered into settlement agreements with two of the three defendants…

DepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsUSAZydus Cadila

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Indian govt plans to support a competitive pharma sector, especially for SMEs

Indian govt plans to support a competitive pharma sector, especially for SMEs

14-04-2014

In a bid to strengthen the existing infrastructure facilities and to enable the Indian pharmaceutical…

Asia-PacificGenericsIndiaMarkets & MarketingPoliticsProduction

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

12-04-2014

US biotech firm Dendreon has released positive preliminary data from a long-term analysis of the Phase…

BiotechnologyDendreonOncologyProvengeResearch

Chugai files NDA for vemurafenib for melanoma

Chugai files NDA for vemurafenib for melanoma

11-04-2014

Japanese drugmaker Chugai Pharmaceutical has filed a new drug application to the Ministry of Health,…

BRAFV600ChemistryChugai PharmaceuticalJapanJO28178OncologyOrganochloridesPharmaceuticalRegulationRoche Diagnosticsvemurafenib

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Despite focus on generics, South Korean pharma market to reach $24.3 billion by 2020

Despite focus on generics, South Korean pharma market to reach $24.3 billion by 2020

10-04-2014

As a result of a high level of access to health care insurance and reimbursement, coupled with increasing…

Asia-PacificGenericsMarkets & MarketingPolitics

Erytech adds a new product candidate to its development portfolio

10-04-2014

French cancer focused drug developer Erytech Pharma has added a new product development candidate, ERY-MET,…

ERY-METErytech PharmaOncologyPharmaceuticalResearch

1 to 25 of 2611 results

Company Spotlight

Fibrotech

Fibrotech

Back to top